Citoxlab signs investment and partnership deal with Experimental Pharmacology and Oncology Berlin-Buch

Citoxlab, a CRO for non-clinical research, has announced an investment and partnership deal with Experimental Pharmacology and Oncology Berlin-Buch (EPO), a CRO providing services for preclinical oncology research.

Dr Jean-François Le Bigot, president and CEO of Citoxlab Group said: ‘We are particularly happy that EPO’s management agreed to our investment proposal. Its scientific reputation and the reliability of its studies are widely recognised in the oncology community. More than 40 per cent of the new drugs under development target cancer. Offering an integrated services portfolio which includes pharmacology alongside drug safety, pharmacokinetics and bioanalysis/biomarkers will allow Citoxlab-EPO’s clients to save time and money and avoid the risks linked to moving from one CRO to another.’

Investment in the German CRO, specialised in the preclinical assessment of new anti-cancer drugs, strengthens Citoxlab’s pharmacology portfolio, which will benefit from synergies in preclinical safety and biomarkers services already provided by Citoxlab

Founded in 1997, EPO is an AAALAC accredited organisation. It provides in vitro and in vivo testing of drug candidates with antitumor and immunostimulatory activities in the oncology field.

Dr Jens Hoffman, CEO of EPO said: ‘As the founders and main shareholders, Dr Iduna Fichner, Professor Wolfgang Walther, CSO, and I have carefully analysed Citoxlab’s interest in our company, with our long-term development in mind. As one of the top five non-clinical CROs worldwide, Citoxlab has established long-lasting business relationships with hundreds of customers. In addition, as a science-driven CRO, Citoxlab has developed specialities in disciplines such as immunohistochemistry, cell cytometry and genomics, which are key in our area of research. We believe that these scientific synergies, combined with Citoxlab’s strong business development dynamics, will benefit both us and our clients. I must add that the respect for the culture and management in their previous acquisitions shown by Citoxlab was important in choosing this strategic partnership, where Citoxlab will own 49 per cent of EPO.’

Twitter icon
Google icon icon
Digg icon
LinkedIn icon
Reddit icon
e-mail icon

Robert Roe reports on developments in AI that are helping to shape the future of high performance computing technology at the International Supercomputing Conference


James Reinders is a parallel programming and HPC expert with more than 27 years’ experience working for Intel until his retirement in 2017. In this article Reinders gives his take on the use of roofline estimation as a tool for code optimisation in HPC


Sophia Ktori concludes her two-part series exploring the use of laboratory informatics software in regulated industries.


As storage technology adapts to changing HPC workloads, Robert Roe looks at the technologies that could help to enhance performance and accessibility of
storage in HPC


By using simulation software, road bike manufacturers can deliver higher performance products in less time and at a lower cost than previously achievable, as Keely Portway discovers